Jochen B Geigl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1993048/publications.pdf

Version: 2024-02-01

304743 501196 3,645 27 22 28 h-index citations g-index papers 30 30 30 6442 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Circulating Tumor DNA as a Liquid Biopsy for Cancer. Clinical Chemistry, 2015, 61, 112-123.	3.2	654
2	Complex Tumor Genomes Inferred from Single Circulating Tumor Cells by Array-CGH and Next-Generation Sequencing. Cancer Research, 2013, 73, 2965-2975.	0.9	497
3	Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Medicine, 2013, 5, 30.	8.2	306
4	Inferring expressed genes by whole-genome sequencing of plasma DNA. Nature Genetics, 2016, 48, 1273-1278.	21.4	295
5	Defining â€~chromosomal instability'. Trends in Genetics, 2008, 24, 64-69.	6.7	268
6	Hematogenous dissemination of glioblastoma multiforme. Science Translational Medicine, 2014, 6, 247ra101.	12.4	264
7	Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing. PLoS Genetics, 2014, 10, e1004271.	3.5	157
8	Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. Nature Communications, 2019, 10, 4666.	12.8	146
9	Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. Nature Communications, 2016, 7, 12008.	12.8	134
10	The potential of liquid biopsies for the early detection of cancer. Npj Precision Oncology, 2017, 1, 36.	5.4	126
11	Circulating tumor cells and DNA as liquid biopsies. Genome Medicine, 2013, 5, 73.	8.2	116
12	The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Research, 2014, 16, 421.	5.0	113
13	Identification of small gains and losses in single cells after whole genome amplification on tiling oligo arrays. Nucleic Acids Research, 2009, 37, e105-e105.	14.5	65
14	Nonâ€invasive detection of genomeâ€wide somatic copy number alterations by liquid biopsies. Molecular Oncology, 2016, 10, 494-502.	4.6	63
15	Single-cell isolation from cell suspensions and whole genome amplification from single cells to provide templates for CGH analysis. Nature Protocols, 2007, 2, 3173-3184.	12.0	60
16	Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. Nature Communications, 2014, 5, 5191.	12.8	51
17	Patient monitoring through liquid biopsies using circulating tumor DNA. International Journal of Cancer, 2017, 141, 887-896.	5.1	46
18	Multiplex-fluorescence in situ hybridization for chromosome karyotyping. Nature Protocols, 2006, 1, 1172-1184.	12.0	42

#	Article	IF	CITATIONS
19	Acute myeloid leukemia with TP53 germ line mutations. Blood, 2016, 128, 2270-2272.	1.4	39
20	Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors. Modern Pathology, 2016, 29, 1262-1277.	5.5	39
21	Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. International Journal of Cancer, 2018, 143, 1236-1248.	5.1	37
22	Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer. ESMO Open, 2020, 5, e000872.	4.5	26
23	Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer. Genome Medicine, 2020, 12, 20.	8.2	25
24	mFast-SeqS as a Monitoring and Pre-screening Tool for Tumor-Specific Aneuploidy in Plasma DNA. Advances in Experimental Medicine and Biology, 2016, 924, 147-155.	1.6	23
25	A novel mutation in <i>ATRX</i> associated with intellectual disability, syndromic features, and osteosarcoma. Pediatric Blood and Cancer, 2017, 64, e26522.	1.5	18
26	Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1in a patient with bilateral breast and endometrial adenocarcinoma. BMC Medical Genetics, 2013, 14, 129.	2.1	17
27	On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer. Npj Precision Oncology, 2020, 4, 30.	5.4	13